타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528) Johnson & Johnson / Legend Biotech·BCMA 29 trials |
|---|---|
Overview Program | Carvykti (ciltacabtagene autoleucel) |
Overview Company | Johnson & Johnson / Legend Biotech |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs. |
Positioning Known limitation | BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche. |
Positioning Development positioning | 2L+ (originally 4L+) |
Technology Vector | Lentiviral |
MoA Mechanism | Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion. |
MoA Biomarker | BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence. |
Toxicology Major finding | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Toxicology CRS | CRS in ~95% of CARTITUDE-1 patients, grade ≥3 ~4% |
Clinical Safety signal | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | ciltacabtagene autoleucel (Carvykti, cilta-cel, LCAR-B38M, JNJ-68284528) Johnson & Johnson / Legend Biotech·BCMA 29 trials |
|---|---|
Overview Program | Carvykti (ciltacabtagene autoleucel) |
Overview Company | Johnson & Johnson / Legend Biotech |
Overview Modality | CGT |
Overview Target | BCMA |
Overview Indication | Relapsed or refractory multiple myeloma |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | Dual-epitope BCMA binding raises avidity and appears to sustain CAR-T persistence longer than single-domain designs. |
Positioning Known limitation | BCMA loss or biallelic deletion, soluble BCMA shedding, T-cell exhaustion, and immunosuppressive marrow niche. |
Positioning Development positioning | 2L+ (originally 4L+) |
Technology Vector | Lentiviral |
MoA Mechanism | Autologous T cells engineered with a dual-epitope BCMA CAR recognize BCMA on malignant plasma cells and trigger MHC-independent cytolysis and clonal CAR-T expansion. |
MoA Biomarker | BCMA expression, MRD negativity at 10⁻⁵, CAR transgene persistence. |
Toxicology Major finding | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Toxicology CRS | CRS in ~95% of CARTITUDE-1 patients, grade ≥3 ~4% |
Clinical Safety signal | Boxed warnings for CRS, ICANS, parkinsonism and Guillain-Barré syndrome, HLH/MAS, prolonged cytopenia, and secondary T-cell malignancy. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교